Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.32 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5345793 | 0.88 | SMYD3 (0.38) | DPP4SMYD3CHRM2CHRM1CHRM3 | |
| SCHEMBL1810381 | 0.85 | NR1H2 (0.33) | LMNADPP4RIPK1 | |
| SCHEMBL18322450 | 0.85 | RIPK1 (0.34) | DPP4RIPK1 | |
| SCHEMBL3586527 | 0.84 | RIPK1 (0.31) | DPP4RIPK1 | |
| SCHEMBL1640341 | 0.84 | RIPK1 (0.31) | DPP4RIPK1 | |
| SCHEMBL25436699 | 0.84 | CHRM1 (0.40) | DPP4SMYD3CHRM2CHRM1CHRM3 | |
| SCHEMBL619575 | 0.83 | TYMP (0.33) | DPP4SMYD3RIPK1 | |
| SCHEMBL28362675 | 0.82 | NR1H2 (0.38) | DPP4CHRM2CHRM1CHRM3 | |
| SCHEMBL2525440 | 0.81 | — | — | |
| SCHEMBL7990391 | 0.81 | PREP (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464287-B1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORP (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11344554-B2 | Animal and human anti-malarial agents | CELGENE CORPORATION (US) | 2022-05-31 | — | — | US | disclosed |
| US-20200330469-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORP (US) | 2020-10-22 | — | — | US | disclosed |
| US-10736899-B2 | Animal and human anti-malarial agents | CELGENE CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-10420771-B2 | Animal and human anti-malarial agents | CELGENE CORPORATION (US) | 2019-09-24 | — | — | US | disclosed |
| EP-3464287-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | Celgene Corporation (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20180280398-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORP (US) | 2018-10-04 | — | — | US | disclosed |
| US-10016436-B2 | Animal and human anti-malarial agents | CELGENE CORPORATION (US) | 2018-07-10 | — | — | US | disclosed |
| WO-2017210399-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORPORATION (US) | 2017-12-07 | — | — | WO | disclosed |
| US-20170348316-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORPORATION | 2017-12-07 | — | — | US | disclosed |
| US-20110256064-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins | AC IMMUNE, S.A. (CH) | 2011-10-20 | — | — | US | disclosed |
| EP-2377860-A1 | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | AC Immune S.A. (CH) | 2011-10-19 | — | — | EP | disclosed |
| EP-1558609-A4 | KINASE INHIBITORS | MERCK & CO INC (US) | 2008-05-28 | — | — | EP | disclosed |
| US-7217716-B2 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | MERCK & CO., INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7053089-B2 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | MERCK & CO., INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1558609-A2 | KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2005033129-A1 | ANTIBACTERIAL AMIDE MACROCYCLES | BAYER HEALTHCARE AG (DE) | 2005-04-14 | — | — | WO | disclosed |
| US-20040209889-A1 | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | MERCK SHARP & DOHME CORP. | 2004-10-21 | — | — | US | disclosed |
| WO-2004041164-A2 | KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20020165241-A1 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | MERCK SHARP & DOHME LLC | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330469-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | HPRT1, UMPS, PNP | NCF1 1449/4885PLG 2777/4885PLAT 2601/4885 |
| US-20170348316-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | HPRT1, NUDT1, UMPS | NCF1 1494/4885PLG 2672/4885PLAT 2765/4885 |
| US-10420771-B2 | Animal and human anti-malarial agents | HPRT1, UMPS, PNP | NCF1 1423/4885PLG 2421/4885PLAT 2537/4885 |
| US-10736899-B2 | Animal and human anti-malarial agents | HPRT1, UMPS, PNP | NCF1 1449/4885PLG 2777/4885PLAT 2601/4885 |
| US-10016436-B2 | Animal and human anti-malarial agents | HPRT1, NUDT1, UMPS | NCF1 1494/4885PLG 2672/4885PLAT 2765/4885 |
| US-20040209889-A1 | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | GRIN1, GRIN2B, GRIN2A | NCF1 376/4885PLG 4738/4885PLAT 4874/4885 |
| US-20110256064-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins | APP, PSEN1, PSEN2 | NCF1 2638/4885PLG 1720/4885PLAT 2958/4885 |
| US-11344554-B2 | Animal and human anti-malarial agents | HPRT1, UMPS, PNP | NCF1 1449/4885PLG 2777/4885PLAT 2601/4885 |
| US-20180280398-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | HPRT1, UMPS, PNP | NCF1 1449/4885PLG 2777/4885PLAT 2601/4885 |
| US-20020165241-A1 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | GRIN1, GRIN2B, GRIN2A | NCF1 367/4885PLG 4747/4885PLAT 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.